摘要
目的分析卡瑞利珠单抗联合SOX化疗方案治疗晚期胃癌患者的效果及对肿瘤标志物水平、生存情况的影响。方法选取2020年2月至2023年4月收治的100例晚期胃癌患者作为研究对象,随机将其分为对照组和观察组,各50例。对照组采用SOX化疗方案治疗,观察组在对照组基础上加用卡瑞利珠单抗治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的癌胚抗原(CEA)、血管内皮生长因子(VEGF)、细胞角蛋白19片段(CYFRA21-1)、糖类抗原19-9(CA19-9)水平低于对照组(P<0.05)。治疗后,观察组的世界卫生组织生存质量测定量表简表(WHOQOL-BREF)各维度评分高于对照组(P<0.05)。观察组的不良反应总发生率低于对照组(P<0.05)。结论卡瑞利珠单抗联合SOX化疗方案治疗晚期胃癌的效果显著,可降低肿瘤标志物水平,改善患者的生存情况,且不会增加不良反应发生风险,值得临床进一步推广和应用。
Objective To analyze the effect of camrelizumab combined with SOX chemotherapy regimen in the treatment of patients with advanced gastric cancer and its influences on tumor marker levels and survival.Methods A total of 100 patients with advanced gastric cancer admitted from February 2020 to April 2023 were selected as the study subjects and randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with SOX chemotherapy regimen,and the observation group was treated with camrelizumab on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and carbohydrate antigen 19-9(CA19-9)in the observation group were lower than those in the control group(P<0.05).After treatment,the scores of each dimension of the World Health Organization Quality of Life-BREF(WHOQOL-BREF)in the observation group were higher than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Camrelizumab combined with SOX chemotherapy regimen is effective in the treatment of advanced gastric cancer.It can reduce the levels of tumor markers,improve survival of patients,and will not increase the risk of adverse reactions,which is worthy of futher clinical promotion and application.
作者
朱金祥
柯东平
郭龙玮
ZHU Jinxiang;KE Dongping;GUO Longwei(Abdominal Oncology Surgery Department,Shaanxi Provincial Cancer Hospital,Xi'an 710061;Oncology Radiotherapy Department,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China)
出处
《临床医学研究与实践》
2024年第26期54-57,共4页
Clinical Research and Practice
